Promising clinical trial results of tucatinib with T-DM1 against HER2+ breast cancer
Phase 1b clinical trial results published in JAMA Oncology show promise for the combination of tucatinib (formerly ONT-380) with T-DM1 against heavily pretreated HER2-positive breast cancer. Of 57 patients treated, 48 percent ...
Jul 10, 2018
0
28